



NMS Labs

CONFIDENTIAL

200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com

Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

Demo Report

Report Issued 03/30/2020 12:01
Last Report Issued 03/09/2009 14:47

88888
Clinical Example Report
Attn: Example Reports
200 Welsh Road
Horsham, PA 19044

Patient Name 1491SP
Patient ID 1491SP
Chain 09001501
Age Not Given DOB Not Given
Gender Not Given
Workorder 09001501
Received 03/09/2009 14:45

Sample ID 09001501-001
Matrix Serum or Plasma
Patient Name 1491SP
Patient ID 1491SP
Container Type Clear vial

Collect Dt/Tm Not Given
Source Not Given

Approx Vol/Weight Not Given

Receipt Notes None Entered

Table with 5 columns: Analysis and Comments, Result, Units, Reporting Limit, Notes

1491SP Desvenlafaxine, Serum/Plasma

Analysis by High Performance Liquid Chromatography/
Tandem Mass Spectrometry (LC-MS/MS)

Table row: Desvenlafaxine, None Detected, ng/mL, 10

Synonym(s): Pristiq®; O-Desmethylvenlafaxine
Mean peak plasma concentrations +/- S.D., obtained at
approximately 7.5 hours after dosing, were reported as
follows:
75 mg (sustained release) oral dose: 135 +/- 54 ng/mL
100 mg (sustained release) oral dose: 238 +/- 45 ng/mL
150 mg (sustained release) oral dose: 284 +/- 83 ng/mL

This test was developed and its performance characteristics determined by NMS Labs. It has not been cleared or approved by the US
Food and Drug Administration.